Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraduodenal indomethacin to prevent post-ERCP pancreatitis in ERCP-naïve patients
KCT0002394Phase 3Recruiting
- Sponsor
- PMG Pharma
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) comparing Intraduodenal indomethacin with Placebo (2 arms). Primary endpoint: Incidence of post-ERCP pancreatitis. Started May 2017; status: recruiting.
02
Drugs
indomethacin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on KCT0002394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002394.